[{"arm_notes": "", "treatment_id": null, "treatment_name": "Immunogenicity; Vaccine;Immunotherapy; Active;Vaccination;Placebos;Injections; Intramuscular;CIGB-66 ;Group 1 (Experimental): CIGB-66 (RBD 50 mcg + aluminum hydroxide 0.30 mg); 0.5 mL intramuscularly in the deltoid region (schedule 0-14-28 days).Group 2 (Control): Placebo; 0.5 mL intramuscularly in the deltoid region (schedule 0-14-28 days).", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 1 (Experimental): CIGB-66 (RBD 50 mcg + aluminum hydroxide 0.30 mg); 0.5 mL intramuscularly in the deltoid region (schedule 0-14-28 days).", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 2 (Control): Placebo; 0.5 mL intramuscularly in the deltoid region (schedule 0-14-28 days).", "treatment_type": "Placebo", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 1975, "treatment_name": "Cigb-66", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "Group 1 (Experimental): CIGB-66 (RBD 50 mcg + aluminum hydroxide 0.30 mg); 0.5 mL intramuscularly in the deltoid region (schedule 0-14-28 days).Group 2 (Control): Placebo; 0.5 mL intramuscularly in the deltoid region (schedule 0-14-28 days).;Immunogenicity; Vaccine;Immunotherapy; Active;Vaccination;Placebos;Injections; Intramuscular;CIGB-66", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 1 (Experimental): CIGB-66 (RBD 50 mcg + aluminum hydroxide 0.30 mg); 0.5 mL intramuscularly in the deltoid region (schedule 0-14-28 days).", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 2 (Control): Placebo; 0.5 mL intramuscularly in the deltoid region (schedule 0-14-28 days).;Immunogenicity; Vaccine;Immunotherapy; Active;Vaccination;Placebos;Injections; Intramuscular;CIGB-66", "treatment_type": "Placebo", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 1975, "treatment_name": "Cigb-66", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}, {"arm_notes": "no third arm", "treatment_id": 1975, "treatment_name": "Cigb-66", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "Immunogenicity; Vaccine;Immunotherapy; Active;Vaccination;Placebos;Injections; Intramuscular;CIGB-66 ;Group 1 (Experimental): CIGB-66 (RBD 50 mcg + aluminum hydroxide 0.30 mg); 0.5 mL intramuscularly in the deltoid region (schedule 0-14-28 days).Group 2 (Control): Placebo; 0.5 mL intramuscularly in the deltoid region (schedule 0-14-28 days).", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 1 (Experimental): CIGB-66 (RBD 50 mcg + aluminum hydroxide 0.30 mg); 0.5 mL intramuscularly in the deltoid region (schedule 0-14-28 days).", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 2 (Control): Placebo; 0.5 mL intramuscularly in the deltoid region (schedule 0-14-28 days).", "treatment_type": "Placebo", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 1975, "treatment_name": "Cigb-66", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "Group 1 (Experimental): CIGB-66 (RBD 50 mcg + aluminum hydroxide 0.30 mg); 0.5 mL intramuscularly in the deltoid region (schedule 0-14-28 days).Group 2 (Control): Placebo; 0.5 mL intramuscularly in the deltoid region (schedule 0-14-28 days).;Immunogenicity; Vaccine;Immunotherapy; Active;Vaccination;Placebos;Injections; Intramuscular;CIGB-66", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 1 (Experimental): CIGB-66 (RBD 50 mcg + aluminum hydroxide 0.30 mg); 0.5 mL intramuscularly in the deltoid region (schedule 0-14-28 days).", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 2 (Control): Placebo; 0.5 mL intramuscularly in the deltoid region (schedule 0-14-28 days).;Immunogenicity; Vaccine;Immunotherapy; Active;Vaccination;Placebos;Injections; Intramuscular;CIGB-66", "treatment_type": "Placebo", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 1975, "treatment_name": "Cigb-66", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "Immunogenicity; Vaccine;Immunotherapy; Active;Vaccination;Placebos;Injections; Intramuscular;CIGB-66 ;Group 1 (Experimental): CIGB-66 (RBD 50 mcg + aluminum hydroxide 0.30 mg); 0.5 mL intramuscularly in the deltoid region (schedule 0-14-28 days).Group 2 (Control): Placebo; 0.5 mL intramuscularly in the deltoid region (schedule 0-14-28 days).", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 1 (Experimental): CIGB-66 (RBD 50 mcg + aluminum hydroxide 0.30 mg); 0.5 mL intramuscularly in the deltoid region (schedule 0-14-28 days).", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 2 (Control): Placebo; 0.5 mL intramuscularly in the deltoid region (schedule 0-14-28 days).", "treatment_type": "Placebo", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "Group 1 (Experimental): CIGB-66 (RBD 50 mcg + aluminum hydroxide 0.30 mg); 0.5 mL intramuscularly in the deltoid region (schedule 0-14-28 days).Group 2 (Control): Placebo; 0.5 mL intramuscularly in the deltoid region (schedule 0-14-28 days).;Immunogenicity; Vaccine;Immunotherapy; Active;Vaccination;Placebos;Injections; Intramuscular;CIGB-66", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 1 (Experimental): CIGB-66 (RBD 50 mcg + aluminum hydroxide 0.30 mg); 0.5 mL intramuscularly in the deltoid region (schedule 0-14-28 days).", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 2 (Control): Placebo; 0.5 mL intramuscularly in the deltoid region (schedule 0-14-28 days).;Immunogenicity; Vaccine;Immunotherapy; Active;Vaccination;Placebos;Injections; Intramuscular;CIGB-66", "treatment_type": "Placebo", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "Group 1 (Experimental): CIGB-66 (RBD 50 mcg + aluminum hydroxide 0.30 mg); 0.5 mL intramuscularly in the deltoid region (schedule 0-14-28 days). Group 2 (Control): Placebo; 0.5 mL intramuscularly in the deltoid region (schedule 0-14-28 days).;Immunogenicity; Vaccine;CIGB-66", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 1 (Experimental): CIGB-66 (RBD 50 mcg + aluminum hydroxide 0.30 mg); 0.5 mL intramuscularly in the deltoid region (schedule 0-14-28 days).", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 2 (Control): Placebo; 0.5 mL intramuscularly in the deltoid region (schedule 0-14-28 days).;Immunogenicity; Vaccine;CIGB-66", "treatment_type": "Placebo", "pharmacological_treatment": "TODO"}]